What is Euro-Med Laboratories Philippines EV-to-FCF?
Euro-Med Laboratories PhilippinesPHS:EURO 82 EV-to-FCF is 8.35 as of Jul. 05, 2026, which is 73% below its 10-year median of 30.59. GuruFocus rates PHS:EURO with a GF Score™ of 82/100 and a GF Value™ of ₱1.02 (Fairly Valued). The stock has 7 warning signs investors should review. Among 562 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 82.38% on this metric.
PHS:EURO'
s EV-to-FCF Range Over the Past 10 Years
Min: -1285.11 Med: 30.59 Max: 920.72
Current: 8.35
During the past 13 years, the highest EV-to-FCF of Euro-Med Laboratories Philippines was 920.72. The lowest was -1285.11. And the median was 30.59.
PHS:EURO's EV-to-FCF is ranked better than 82.38% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.525
vs PHS:EURO: 8.35
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Euro-Med Laboratories Philippines's PE Ratio (TTM) for today is calculated as:
Euro-Med Laboratories Philippines's share price for today is ₱1.10.
Euro-Med Laboratories Philippines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₱0.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Euro-Med Laboratories Philippines EV-to-FCF Related Terms
Euro-Med Laboratories Philippines EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's EV-to-FCF falls into.
Euro-Med Laboratories Philippines's current Enterprise Value is ₱6,973 Mil.
Euro-Med Laboratories Philippines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₱835 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines (PHS:EURO) has a EV-to-FCF of 8.35 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Euro-Med Laboratories Philippines and its competitors. This is 73% below median its historical median of 30.59. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #99 out of 562 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is Euro-Med Laboratories Philippines' EV-to-FCF too high?
Euro-Med Laboratories Philippines' current EV-to-FCF of 8.35 is 73% below median its 10-year median of 30.59. The Drug Manufacturers industry median EV-to-FCF is 20.53. Euro-Med Laboratories Philippines' value of 8.35 is 59.3% below this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #99 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #99 out of 562 companies for EV-to-FCF. This places Euro-Med Laboratories Philippines in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.53. Euro-Med Laboratories Philippines' value of 8.35 is 59.3% below this benchmark. While the company's 10-year median is 30.59 vs. the industry median of 20.53, Euro-Med Laboratories Philippines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.53, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current EV-to-FCF of 8.35 is 59.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current EV-to-FCF is 8.35, which is 73% below median its own 10-year median of 30.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.02, compared to a current price of ₱1.10 — trading 7.8% above its estimated fair value. The current EV-to-FCF is 8.35, which is 73% below median its 10-year median of 30.59 and 59.3% below the Drug Manufacturers industry median of 20.53. Euro-Med Laboratories Philippines' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current EV-to-FCF is 8.35 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.10 is trading 7.8% above its estimated GF Value™ of ₱1.02.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
EV-to-FCF: 8.35 (73% below median its 10-year median of 30.59)
GF Value™: ₱1.02 vs. price of ₱1.10 (7.8% above fair value)
Industry Position: 59.3% below the Drug Manufacturers median (#99 of 562)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Business Description
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
82GF Score
Get the complete analysis for PHS:EURO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
